These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 14597946)

  • 1. Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure.
    De Tommasi E; Iacoviello M; Romito R; Ceconi C; Guida P; Massari F; Francolini G; Bertocchi F; Ferrari R; Rizzon P; Pitzalis MV
    Am Heart J; 2003 Nov; 146(5):E17. PubMed ID: 14597946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Cohn JN; Tognoni G;
    N Engl J Med; 2001 Dec; 345(23):1667-75. PubMed ID: 11759645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial.
    Cohn JN; Anand IS; Latini R; Masson S; Chiang YT; Glazer R;
    Circulation; 2003 Sep; 108(11):1306-9. PubMed ID: 12939207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Reed SD; Friedman JY; Velazquez EJ; Gnanasakthy A; Califf RM; Schulman KA
    Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
    Baruch L; Anand I; Cohen IS; Ziesche S; Judd D; Cohn JN
    Circulation; 1999 May; 99(20):2658-64. PubMed ID: 10338459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT).
    Baruch L; Glazer RD; Aknay N; Vanhaecke J; Heywood JT; Anand I; Krum H; Hester A; Cohn JN
    Am Heart J; 2004 Dec; 148(6):951-7. PubMed ID: 15632877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissociation between ACE activity and autonomic response to ACE inhibition in patients with heart failure.
    Binkley PF; Nunziata E; Haas GJ; Starling RC; Leier CV; Cody RJ
    Am Heart J; 2000 Jul; 140(1):34-42. PubMed ID: 10874261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valsartan in chronic heart failure.
    Ripley TL
    Ann Pharmacother; 2005 Mar; 39(3):460-9. PubMed ID: 15687480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of angiotensin converting enzyme inhibitor lisinopril on sympathetic heart rate response during exercise in the early phase of acute myocardial infarction].
    Akashi Y; Tanabe K; Osada N; Samejima H; Seki A; Yokoyama Y; Nakayama M; Suzuki N; Oomiya K; Itoh H; Miyake F; Murayama M
    J Cardiol; 2000 Oct; 36(4):221-9. PubMed ID: 11079227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Valsartan on hospitalization: results from Val-HeFT.
    Carson P; Tognoni G; Cohn JN
    J Card Fail; 2003 Jun; 9(3):164-71. PubMed ID: 12815565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group.
    Bakris GL; Siomos M; Richardson D; Janssen I; Bolton WK; Hebert L; Agarwal R; Catanzaro D
    Kidney Int; 2000 Nov; 58(5):2084-92. PubMed ID: 11044229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect of monotherapy (data from the trial SADKO-CHF)].
    Skvortsov AA; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Mareev VIu; Belenkov IuN
    Ter Arkh; 2005; 77(8):34-43. PubMed ID: 16206603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of angiotensin-converting enzyme inhibitor versus valsartan on cellular signaling events in heart transplant.
    White M; Ross H; Levesque S; Whittom L; Pelletier GB; Racine N; Meloche S; Voisin L
    Ann Pharmacother; 2009 May; 43(5):831-9. PubMed ID: 19417110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of the neurohormonal system and its relationship to autonomic abnormalities in decompensated heart failure.
    Burger AJ; Aronson D
    J Card Fail; 2001 Jun; 7(2):122-8. PubMed ID: 11420763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valsartan restores sarcoplasmic reticulum function with no appreciable effect on resting cardiac function in pacing-induced heart failure.
    Okuda S; Yano M; Doi M; Oda T; Tokuhisa T; Kohno M; Kobayashi S; Yamamoto T; Ohkusa T; Matsuzaki M
    Circulation; 2004 Feb; 109(7):911-9. PubMed ID: 14757694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
    J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis.
    Smith DG; Cerulli A; Frech FH
    Clin Ther; 2005 Jun; 27(6):951-9. PubMed ID: 16117995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neurohumoral activation, regulation of sodium excretion and vasodilator treatment in heart insufficiency].
    Pimenta J; Pereira M; Castro A; Dias P; Azevedo A; Bettencourt P; Ferreira A
    Rev Port Cardiol; 2002 Feb; 21(2):157-62. PubMed ID: 11963285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.